Breaking Finance News

Biogen Inc (NASDAQ:BIIB) target price raised to $304.98, reported today by Vetr Inc.

Biogen Inc (NASDAQ:BIIB) had its target price raised to $304.98 by Vetr Inc. in a report released Thursday July 06, 2017. The new target price indicates a possible upside of 0.10% based on the company's last stock close price.

Previously on 07/05/2017, Vetr Inc. reported about Biogen Inc (NASDAQ:BIIB) raised the target price from $0.00 to $309.45. At the time, this indicated a possible upside of 0.11%.

Yesterday Biogen Inc (NASDAQ:BIIB) traded 0.90% higher at $277.71. The company’s 50-day moving average is $281.49 and its 200-day moving average is $273.98. The last stock close price is up 3.54% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 727,172 shares of the stock were exchanged, down from an average trading volume of 1,461,070

See Chart Below

Biogen Inc (NASDAQ:BIIB)

Biogen Inc has a 52 week low of $244.28 and a 52 week high of $304.23 with a P/E ratio of 18.61 The company’s market cap is currently $0.

In addition to Vetr Inc. reporting its target price, a total of 19 firms have reported on the stock. The consensus target price is $333.47 with 6 firms rating the stock a strong buy, 8 firms rating the stock a buy, 9 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Biogen Inc (NASDAQ:BIIB)

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.